• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Monday, March 8, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Immunology

New study gives hope of eliminating mother-to-baby transmission of HIV

Bioengineer by Bioengineer
February 12, 2021
in Immunology
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Karolinska Institutet.

Anti-retroviral drugs are a vital tool in the prevention and treatment of HIV. A new study of pregnant women in Tanzania shows that life-long antiviral treatment also seems to prevent viral transmission from mother to baby. The results of the study, which was conducted in part by researchers at Karolinska Institutet in Sweden and published in Lancet HIV, make a promising contribution to the WHO’s work with HIV prevention in low and middle-income countries.

Just over eight years ago, the World Health Organisation (WHO) issued recommendations known as Option B+ for a simpler and more effective prevention and treatment for HIV during and beyond pregnancy in low and middle-income countries.

One arm of the Option B+ programme involved ensuring that pregnant women with HIV were started on a life-long regimen of antiviral drugs, ART, as early as possible during their pregnancy. Option B+ made an important breakthrough in the prevention of the mother-to-baby transmission of HIV.

Lifelong ART intervention can also provide effective protection against progression to more advanced HIV and early death, and prevent the further infection of partners and future children.

To date, however, research on how the treatment affects long-term viral levels in pregnant women with HIV in low and middle -income countries with a high HIV burden has been scant.

Now, researchers at Karolinska Institutet, Muhimbili University of Health and Allied Sciences and Management and Development for Health, have examined the effectiveness over time of Option B+ intervention in Tanzania.

According to UNAIDS figures from 2019, 4.8 percent of the Tanzanian population between the ages of 15 and 49, that is 1.7 million people, live with HIV.

The study, which was conducted in Dar es Salaam – Tanzania’s largest city – included patient data for 10,161 pregnant women with HIV who had begun antiviral treatment on the Option B+ programme to prevent viral transmission to their unborn babies.

At the time of data collection, 5.9 per cent of the city’s pregnant women starting antenatal care were HIV-positive. About a third of the study participants had advanced HIV disease.

The researchers measured the level of HIV in the women’s blood to gauge the effectiveness of the antiviral treatment over time. The data was collected between 2014 and 2016, and the women were monitored for up to four years.

The results showed that up to 90 percent of the women under study had suppressed viral levels up to four years after starting Option B+ care. In other words, it seems possible that the WHO goal of eliminating transmission from mother to baby can be achieved.

“Our study confirms the lasting health benefits of life-long ART for women who go on Option B+ during pregnancy and therefore for their babies, too,” says Goodluck Lyatuu, doctor and doctoral student at the Department of Global Public Health, Karolinska Institutet, and the study’s first author. He continues:

“The results also point to some other important challenges when it comes to deriving the full long-term benefits of Option B+. To focus, for example, on some sub-groups of women, such as young mothers, mothers who start ante-natal care late during pregnancy and mothers with advanced HIV.”

###

The study was financed by the Swedish International Development Cooperation Agency (Sida). There are no reported conflicts of interest.

Publication: “Long-term virological outcomes in women who started option B+ care during pregnancy for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania: a cohort study”, Goodluck W Lyatuu, Shally Z Mwashemele, Roseline Urrio, Helga Naburi, Nassir Kashmir, Lameck Machumi, Ayoub Kibao, Ziada Sellah, Nzovu Ulenga, Nicola Orsini, Gunnel Biberfeld, Charles Kilewo, Anna Mia Ekstrom. Lancet HIV, online 11 February 2021, doi: 10.1016/ S2352-3018(20)30308-8.

Media Contact
Press Office, Karolinska Institutet
[email protected]

Original Source

http://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30308-8/fulltext

Related Journal Article

http://dx.doi.org/10.1016/S2352-3018(20)30308-8

Tags: AIDS/HIVDisease in the Developing WorldEpidemiologyInfectious/Emerging DiseasesMedicine/HealthPublic Health
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

Time needed to sequence key molecules could be reduced from years to minutes

March 8, 2021
IMAGE

Monoclonal antibody “cocktail” blocks COVID-19 variants: Study

March 5, 2021

Int’l Women’s Day: Fathima Wakeel to present at Women in Data Science Conference

March 4, 2021

A new strategy for pooling COVID-19 tests to detect outbreaks early

March 4, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    703 shares
    Share 281 Tweet 176
  • People living with HIV face premature heart disease and barriers to care

    86 shares
    Share 34 Tweet 22
  • HIV: an innovative therapeutic breakthrough to optimize the immune system

    36 shares
    Share 14 Tweet 9
  • Global analysis suggests COVID-19 is seasonal

    39 shares
    Share 16 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Chemistry/Physics/Materials SciencesInfectious/Emerging DiseasesGeneticsTechnology/Engineering/Computer SciencecancerPublic HealthMedicine/HealthEcology/EnvironmentBiologyCell BiologyMaterialsClimate Change

Recent Posts

  • Research pinpoints unique drug target in antibiotic resistant bacteria
  • How fast is the universe expanding? Galaxies provide one answer.
  • Young white-tailed deer that disperse survive the same as those that stay home
  • Complement inhibition reverses mental losses in preclinical traumatic brain injury models
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In